ATE397450T1 - Sulfat-konjugate der ursodeoxycholsäure und deren nützliche verwendung bei entzündlichen erkrankungen und anderen anwendungen - Google Patents

Sulfat-konjugate der ursodeoxycholsäure und deren nützliche verwendung bei entzündlichen erkrankungen und anderen anwendungen

Info

Publication number
ATE397450T1
ATE397450T1 AT96940516T AT96940516T ATE397450T1 AT E397450 T1 ATE397450 T1 AT E397450T1 AT 96940516 T AT96940516 T AT 96940516T AT 96940516 T AT96940516 T AT 96940516T AT E397450 T1 ATE397450 T1 AT E397450T1
Authority
AT
Austria
Prior art keywords
udca
sulfate
tauro
disulfate
glyco
Prior art date
Application number
AT96940516T
Other languages
English (en)
Inventor
Kenneth Setchell
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Application granted granted Critical
Publication of ATE397450T1 publication Critical patent/ATE397450T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
AT96940516T 1995-11-21 1996-11-19 Sulfat-konjugate der ursodeoxycholsäure und deren nützliche verwendung bei entzündlichen erkrankungen und anderen anwendungen ATE397450T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/560,992 US5763435A (en) 1995-11-21 1995-11-21 Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders

Publications (1)

Publication Number Publication Date
ATE397450T1 true ATE397450T1 (de) 2008-06-15

Family

ID=24240215

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940516T ATE397450T1 (de) 1995-11-21 1996-11-19 Sulfat-konjugate der ursodeoxycholsäure und deren nützliche verwendung bei entzündlichen erkrankungen und anderen anwendungen

Country Status (15)

Country Link
US (2) US5763435A (de)
EP (1) EP0871452B1 (de)
JP (3) JP3836148B2 (de)
KR (1) KR19990071521A (de)
CN (2) CN101569632A (de)
AT (1) ATE397450T1 (de)
AU (1) AU709594B2 (de)
BR (1) BR9611606A (de)
CA (1) CA2238040C (de)
DE (1) DE69637556D1 (de)
EA (1) EA199800399A1 (de)
NO (2) NO317063B1 (de)
NZ (1) NZ323274A (de)
PL (1) PL186393B1 (de)
WO (1) WO1997018816A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
DK1158989T3 (da) * 1999-03-09 2007-10-22 Anker Stefan Anvendelse af inhibitorer af endotoksin til behandling af kakeksi
PL357674A1 (en) * 2000-04-19 2004-07-26 Thomas Julius Borody Compositions and therapies for hyperlipidaemia-associated disorders
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
ITTO20020102A1 (it) * 2002-02-06 2003-08-06 Abc Ist Biolog Chem Spa Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
CN100421656C (zh) * 2002-11-07 2008-10-01 明尼苏达大学评议会 乌索脱氧胆酸在制备治疗与出血相关的神经系统损伤的药物中的用途
ITMI20030822A1 (it) * 2003-04-18 2004-10-19 Erregierre Spa Processo per la preparazione dell'acido ursodesossicolico
EP2182856A2 (de) 2007-08-08 2010-05-12 Brian J. Cavanaugh Verfahren und vorrichtung für ligaturnaht
EP2208497A1 (de) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Ursodesoxycholsäure (UDCA) zum Verbessern des allgemeinen Gesundheitszustands eines Tumorpatienten
IT1393095B1 (it) 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
WO2011053048A2 (ko) * 2009-10-29 2011-05-05 연세대학교 산학협력단 신규 혈관누출 차단제
JPWO2011096438A1 (ja) * 2010-02-03 2013-06-10 国立大学法人 東京大学 腸疾患の治療方法及び治療用医薬組成物
US9724357B2 (en) 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
KR101953298B1 (ko) * 2017-07-18 2019-02-28 의료법인 성광의료재단 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물
AU2020282288A1 (en) * 2019-05-31 2021-12-02 Metabolon, Inc. Mass spectrometry assay methods for detection of metabolites
CN117949648A (zh) * 2024-03-26 2024-04-30 中国医学科学院北京协和医院 一种用于检测溃疡性结肠炎的标志物及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof

Also Published As

Publication number Publication date
WO1997018816A2 (en) 1997-05-29
NZ323274A (en) 2000-07-28
CN100556408C (zh) 2009-11-04
PL326931A1 (en) 1998-11-09
AU709594B2 (en) 1999-09-02
WO1997018816A3 (en) 1997-06-26
AU7737796A (en) 1997-06-11
NO982281L (no) 1998-07-08
JP2011006445A (ja) 2011-01-13
CA2238040A1 (en) 1997-05-29
JP2006117698A (ja) 2006-05-11
CN1211185A (zh) 1999-03-17
EA199800399A1 (ru) 1998-12-24
JP4630195B2 (ja) 2011-02-09
JP2000500764A (ja) 2000-01-25
US5763435A (en) 1998-06-09
BR9611606A (pt) 2000-10-24
JP5277221B2 (ja) 2013-08-28
EP0871452A2 (de) 1998-10-21
PL186393B1 (pl) 2004-01-30
JP3836148B2 (ja) 2006-10-18
MX9803988A (es) 1998-10-31
NO20042284L (no) 2004-06-02
CN101569632A (zh) 2009-11-04
NO317063B1 (no) 2004-08-02
NO982281D0 (no) 1998-05-19
CA2238040C (en) 2004-07-13
US6251884B1 (en) 2001-06-26
EP0871452B1 (de) 2008-06-04
KR19990071521A (ko) 1999-09-27
NO20042284D0 (no) 2004-06-02
DE69637556D1 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE397450T1 (de) Sulfat-konjugate der ursodeoxycholsäure und deren nützliche verwendung bei entzündlichen erkrankungen und anderen anwendungen
Kojima et al. Comparative effects of three chelating agents on distribution and excretion of cadmium in rats
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
DE60302348D1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
BRPI0510044B8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
Ueda et al. ENOS deficiency causes podocyte injury with mitochondrial abnormality
Wollina et al. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix
Van Molle et al. Protection of zinc against tumor necrosis factor–induced lethal inflammation depends on heat shock protein 70 and allows safe antitumor therapy
KR940021064A (ko) 프레그네인 유도체의 사용 방법
BRPI0416591A (pt) métodos e reagentes para o tratamento de distúrbios inflamatórios
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
US20060063836A1 (en) Method for treating renal disease
Huet et al. Bioavailabllity of lidocaine in normal volunteers and cirrhotic patients
Ishizaki et al. Effect of sodium tauroursodeoxycholate (UR-906) on liver dysfunction in bile duct-ligated rats
Palmer The significance of bile salts metabolism
US20070292533A1 (en) Copper lowering treatment of autoimmune diseases
Gruen Iron uptake in human keratinocytes exposed to photodegraded nifedipine
Koziorowski et al. Ferritin in parkinsonian and control brains
Twedt Treatment of chronic hepatitis and management of biliary tract disorders
Toborek et al. Macrophage migration inhibitor factor (MIF) can induce oxidative injury and apoptotic cell death of spinal cord neurons
Lipińska et al. Total antioxidant capacity of human blood plasma from healthy adults
Sarnowska et al. Mechanisms of neuroprotection in hippocampal organotypic culture
Moiseenok et al. Biotransformation of D‐panthenol and its action in protection of activation of oxidizing processes in brain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties